Becton, Dickinson and Company (NYSE:BDX) authorized to pursue a plan to separate BD’s Biosciences and Diagnostic Solutions ...

BD plans to separate its Biosciences and Diagnostic Solutions unit into an independent company by fiscal 2026.

After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest ...

Becton Dickinson said it would focus on medtech and prioritize research, acquisitions and high-growth markets.

BD (NYSE: BDX) announced that its board unanimously authorized management to pursue the separation of its Life Sciences business.

At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website, investors.bd.com or by phone at 1-800-839-2486 for domestic calls and area ...

Q1 2025 Management View Tom Polen emphasized several key updates, including the planned separation of BD’s Biosciences and Diagnostic Solutions businesses, which aims to create two strategically ...

The board of directors of Franklin Lakes-based, global medical technology company BD, has unanimously authorized BD management ...

Earnings Per Share (EPS) of $3.43, beating the estimated $3 and showing significant growth from the previous year’s $2.68. Revenue reached approximately $5.17 billion, surpassing the estimated $5.10 ...

Becton Dickinson (BDX) stock slid 3% after the company released its fiscal Q1 earnings report and confirmed it was splitting the company into two separate entities.

BofA analyst Travis Steed raised the firm’s price target on Becton Dickinson (BDX) to $269 from $265 and keeps a Buy rating on the shares after ...

Becton Dickinson & Co. said it’s planning to separate part of its life sciences segment in a move aimed at raising the medical technology company’s stock.